Polycythemia vera (PV) is a rare blood cancer causing the bone marrow to make too many blood cells. Treatment usually starts with phlebotomy and may continue with medications. If one treatment isn’t ...

The current landscape of treatment for polycythemia vera is to reduce the risk of blood clotting and control blood counts. However, future treatments will need to go beyond that and target MPN stem ...

panelist discusses how polycythemia vera (PV) treatment approaches include both therapeutic phlebotomy and medications like hydroxyurea or interferon to control blood counts, with treatment selection ...

Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to overproduction of various blood cells. In this interview, Andrew Kuykendall, MD, ...

A breakthrough in the treatment of polycythemia vera, a rare and life-threatening blood cancer, has emerged with the introduction of a new drug named rusfertide. Polycythemia vera falls under the ...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...

Please provide your email address to receive an email when new articles are posted on . In this video, John Mascarenhas, MD, discussed the RuxoBEAT study into ruxolitinib treatment in patients with ...

NEWARK, Calif., Dec. 7, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced the results of a large-scale analysis of real world treatment patterns for polycythemia vera, ...

The current treatment landscape of polycycthemia vera (PV) hinges on treatments like hydroxyurea and ruxolitinib, the latter having emerged as an effective second-line therapy in patients with severe ...

Hi. I'm Ron. I'm a polycythemia patient. I was diagnosed at the age of 38 and have been living with the disease for over 25 years. As you go along with your treatment as a polycythemia patient, you ...

Polycythemia vera (PV), which is marked by an increased number of red blood cells, is a rare blood cancer known to be associated with a high risk of cardiovascular disease. Median survival is ...